Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and Ozempic, could have “an antidepressant effect,” suggesting ...
Health insurance companies are lobbying against proposals that would expand prescription access to weight-loss medications.
Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...
The agriculture community needs to focus on the implications of the use of weight-loss drugs and the world reaching “peak” ...
Nearly one-third of adult employees would change jobs in order to gain coverage. As the demand for GLP-1 weight loss ...
That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...
GLP-1 drugs like Ozempic/Wegovy don’t increase a person’s risk of suicidal actions or thoughts, a new study has conclu ...
Diabetes and obesity are growing health concerns worldwide. A type of medication called GLP-1 receptor agonists, commonly ...
Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...